Empagliflozin improves cardiorespiratory fitness in type 2 diabetes: Translational implications

Canadian Journal of Physiology and Pharmacology

Volumn 96, Issue 11, 2018, Pages 1184-1187

  Kumar, Naresh ^a   Garg, Ankit ^b   Bhatt, Deepak L ^c   Sabongui, Sandra ^d   Gupta, Naveen ^d   Chaudhry, Sundeep ^e   Arena, Ross ^f   Verma, Subodh ^d  

^a Whitby Cardiovascular Institute   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e Division of Clinical Research   (United States)

^f UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Cardiorespiratory fitness; Diabetes; Heart failure; Heart function; SGLT2 inhibitor

Indexed keywords

EMPAGLIFLOZIN; HEMOGLOBIN A1C; BENZHYDRYL DERIVATIVE; BIOLOGICAL MARKER; GLUCOSIDE;

AGED; ARTICLE; CARDIOPULMONARY EXERCISE TEST; CARDIORESPIRATORY FITNESS; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; GLYCEMIC CONTROL; HEART FUNCTION; HUMAN; LUNG MINUTE VOLUME; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXYGEN CONSUMPTION; PRIORITY JOURNAL; CLINICAL TRIAL; DRUG THERAPY; EXERCISE TEST; HEART FAILURE; HEART RATE; MIDDLE AGED; PATHOPHYSIOLOGY; PHARMACOLOGY; TREATMENT OUTCOME;

AGED; BENZHYDRYL COMPOUNDS; BIOMARKERS; CARDIORESPIRATORY FITNESS; DIABETES MELLITUS, TYPE 2; EXERCISE TEST; FEMALE; GLUCOSIDES; HEART FAILURE; HEART RATE; HUMANS; MALE; MIDDLE AGED; OXYGEN CONSUMPTION; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; TREATMENT OUTCOME;

EID: 85055845388     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/cjpp-2018-0359     Document Type: Article

References (13)

1. Beaver, W.L., Wasserman, K., and Whipp, B.J. 1986. A new method for detecting anaerobic threshold by gas exchange. J. Appl. Physiol. 60(6): 2020–2027. doi: 10.1152/jappl.1986.60.6.2020. PMID:3087938.
2. Byrne, N.J., Parajuli, N., Levasseur, J.L., Boisvenue, J., Beker, D.L., Masson, G., et al. 2017. Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure. JACC Basic Transl. Sci. 2(4): 347–354. doi:10.1016/j.jacbts.2017.07.003. PMID:30062155.
3. Chaudhry, S., Arena, R., Wasserman, K., Hansen, J.E., Lewis, G.D., Myers, J., et al. 2009. Exercise-induced myocardial ischemia detected by cardiopulmonary exercise testing. Am. J. Cardiol. 103(5): 615–619. doi:10.1016/j.amjcard.2008. 10.034. PMID:19231322.
4. Chaudhry, S., Arena, R., Bhatt, D.L., Verma, S., and Kumar, N. 2018. A practical clinical approach to utilize cardiopulmonary exercise testing in the evaluation and management of coronary artery disease. Curr. Opin. Cardiol. 33(2): 168–177. PMID:29240566.
5. Farkouh, M.E., and Verma, S. 2018. Prevention of heart failure with SGLT-2 inhibition. JACC, 71(22): 2507–2510. doi:10.1016/j.jacc.2018.02.078. PMID: 29852974.
6. Guazzi, M., and Arena, R. 2009. The impact of pharmacotherapy on the cardiopulmonary exercise test response in patients with heart failure: a mini review. Curr. Vasc. Pharmacol. 7(4): 557–569. doi:10.2174/157016109789043955. PMID:19485908.
7. Neal, B., Perkovic, V., Mahaffey, K.W., de Zeeuw, D., Fulcher, G., Erondu, N., et al. 2017. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377: 644–657. doi:10.1056/NEJMoa1611925. PMID:28605608.
8. Ross, R., Blair, S.N., Arena, R., Church, T.S., Després, J.P., Franklin, B.A., et al. 2016. Importance of assessing cardiorespiratory fitness in clinical practice: a case for fitness as a clinical vital sign: a scientific statement from the American Heart Association. Circulation, 134(24): e653–e699. doi:10.1161/CIR. 0000000000000461. PMID:27881567.
9. Verma, S., and McMurray, J.J.V. 2018. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia, 61(10): 2108–2117. doi:10.1007/s00125-018-4670-7. PMID:30132036.
10. Verma, S., McMurray, J.J.V., and Cherney, D.Z.I. 2017. The metabolodiuretic promise of sodium-dependent glucose co-transporter 2 inhibition. JAMA Cardiol. 2(9): 939–940. doi:10.1001/jamacardio.2017.1891. PMID:28636701.
11. Verma, S., Mazer, C.D., Fitchett, D., Inzucchi, S.E., Pfarr, E., George, J.T., and Zinman, B. 2018. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial. Diabetologia, 61(8): 1712–1723. doi:10.1007/s00125-018-4644-9.PMID:29777264.
12. Wasserman, K., Sue, D., Stringer, W., and Whipp, B.J. 2012. Principles of exercise testing and interpretation: including pathophysiology and clinical applications. 5th ed. Lippincott Williams and Wilkins, Philadelphia.
13. Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. 2015. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373: 2117–2128. doi:10.1056/NEJMoa1504720. PMID:26378978.